Literature DB >> 10094882

The expression of type I growth factor receptors in the squamous neoplastic changes of uterine cervix.

J L Chang1, Y P Tsao, D W Liu, C P Han, W H Lee, S L Chen.   

Abstract

AIM: The type I family of growth factor receptors includes ErbB1, ErbB2, ErbB3, and ErbB4 which are frequently overexpressed in various human cancer cells. In this study, we systematically investigated the frequency and distribution of these four receptors in relation to neoplastic changes and tumor behaviors in the uterine cervix. MATERIALS: A total 84 of cases including 12 cases of normal cervical tissues, 6 cases of low grade squamous intraepithelial lesion, 10 cases of high grade squamous intraepithelial lesion, and 56 cases of squamous cells carcinoma were examined.
RESULTS: Our results show significant difference with increasing grades of dysplasia in terms of these four receptor expressions. No association was found between these four receptors and cell keratinization/differentiation of squamous cell carcinoma of the cervix. Of the four receptors studied, only the expression of erbB2/neu gene was significantly associated with lymph nodal metastasis. Moreover, we find that the coexpression of ErbB1 and ErbB4 was significant in cervical carcinoma.
CONCLUSIONS: The coexpression of ErbB1 and ErbB4 in cervical carcinoma suggests that they may be involved in receptor heterodimerization leading to the activation of signaling pathway in the cervical carcinoma. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10094882     DOI: 10.1006/gyno.1998.5301

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  6 in total

Review 1.  ErbB-4: a receptor tyrosine kinase.

Authors:  W Zhou; G Carpenter
Journal:  Inflamm Res       Date:  2002-02       Impact factor: 4.575

Review 2.  Rationale and clinical experience with epidermal growth factor receptor inhibitors in gynecologic malignancies.

Authors:  Ami P Vaidya; Aric D Parnes; Michael V Seiden
Journal:  Curr Treat Options Oncol       Date:  2005-03

3.  Genetic variations in EGFR and ERBB4 increase susceptibility to cervical cancer.

Authors:  Duanduan Ma; Raymond L Hovey; Zhengyan Zhang; Samantha Fye; Phyllis C Huettner; Ingrid B Borecki; Janet S Rader
Journal:  Gynecol Oncol       Date:  2013-08-06       Impact factor: 5.482

4.  Methylation status of insulin-like growth factor-binding protein 7 concurs with the malignance of oral tongue cancer.

Authors:  Li-Hsuen Chen; Dai-Wei Liu; Junn-Liang Chang; Peir-Rong Chen; Lee-Ping Hsu; Hon-Yi Lin; Yu-Fu Chou; Chia-Fong Lee; Miao-Chun Yang; Yu-Hsuan Wen; Wen-Lin Hsu; Ching-Feng Weng
Journal:  J Exp Clin Cancer Res       Date:  2015-02-24

5.  HER2 expression in cervical cancer as a potential therapeutic target.

Authors:  Alma Chavez-Blanco; Victor Perez-Sanchez; Aurora Gonzalez-Fierro; Teresa Vela-Chavez; Myrna Candelaria; Lucely Cetina; Silvia Vidal; Alfonso Dueñas-Gonzalez
Journal:  BMC Cancer       Date:  2004-09-01       Impact factor: 4.430

6.  HER-2 overexpression/amplification in Barrett's oesophagus predicts early transition from dysplasia to adenocarcinoma: a clinico-pathologic study.

Authors:  Elisa Rossi; Salvatore Grisanti; Vincenzo Villanacci; Domenico Della Casa; Paolo Cengia; Guido Missale; Luigi Minelli; Michela Buglione; Renzo Cestari; Gabrio Bassotti
Journal:  J Cell Mol Med       Date:  2008-10-06       Impact factor: 5.310

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.